Substance / Medication

Alosetron

Overview

Active Ingredient
alosetron
RxNorm CUI
85248

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.
Cremonini F, Delgado-Aros S, Camilleri M · Neurogastroenterol Motil · 2003
PMID: 12588472Meta-Analysis
The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome.
Nakai A, Diksic M, Kumakura Y et al. · Neurogastroenterol Motil · 2005
PMID: 15787942Trial
A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
Chang Lin, Ameen Vanessa Z, Dukes George E et al. · Am J Gastroenterol · 2005
PMID: 15654790Trial
Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.
Lembo Anthony J, Olden Kevin W, Ameen Vanessa Z et al. · Clin Gastroenterol Hepatol · 2004
PMID: 15290660Trial
Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Lotronex).
Koch Kevin, Campanella Corinne, Baidoo Charlotte A et al. · Dig Dis Sci · 2004
PMID: 15387353Trial
Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
Chey William D, Chey William Y, Heath Amy T et al. · Am J Gastroenterol · 2004
PMID: 15555002Trial
Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors.
Koch K M, Corrigan B W, Manzo J et al. · Aliment Pharmacol Ther · 2004
PMID: 15233703Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Alosetron (substance)
SNOMED CT
116509006
UMLS CUI
C0291772
RxNorm CUI
85248

Clinical Data

This intervention maps to 6 entities in the Ltrl knowledge graph.

1
Conditions
2
Biomarkers
2
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Alosetron: Uses, Evidence & Side Effects | Ltrl